ClinicalTrials.gg
RecruitingNCT05876975Updated May 26, 2023

Vaginal Axis on Magnetic Resonance Imaging After Laparoscopic Pectopexy Surgery: a Controlled Study

An interventional study of laparoscopic pectopexy in Pelvic Organ Prolapse, sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization. Recruiting at 1 site in Turkey. Open to female participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-26.

Sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2023, 3 years 5 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Jan 2023, registered May 2023).
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Pelvic Organ Prolapse with a site in Turkey — 5 open to participants now, 6 under way, 1 of them phase 3. Pelvic Organ Prolapse · Turkey.

Planned enrollment
25th of 26
21 · median 55
Started
2023
with 5 others
No phase
25 of 40
5 open now
Registered
21st of 40
by date
Lead sponsor
2 of 40
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization

Among the 40 studies in Pelvic Organ Prolapse with a site in Turkey, this one is the 25th largest by planned enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2023, is one of 25 with no phase, and was the 21st registered.

Pelvic Organ Prolapse

522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.

Browse Pelvic Organ Prolapse studies →

Open to participants now

5 of the 40 studies in Pelvic Organ Prolapse with a site in Turkey are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Pelvic Organ Prolapse with a site in Turkey, or all of them as a file.
02

Study summary

Pelvic organ prolapse (POP) is a major public health concern that adversely affects the physical and psychological well-being of women. In fact, the lifetime risk of POP surgery is 12.6%, highlighting the magnitude of the problem. The most common form of POP involves defects in the anterior vaginal wall accompanied by apical prolapse. The primary objective of surgical treatment for POP is to mitigate symptoms and restore the pelvic support anatomy. Normally, the vaginal axis is directed posteriorly towards the S3 and S4 vertebrae, lying relatively horizontally to the levator plate, and forming an angle of about 130º between the middle and lower vagina. Although sacrocolpopexy (SCP) is considered the gold standard for treating POP, it alters the normal anatomical position of the vaginal axis towards the sacral promontory, which may increase the abdominal pressure load on the anterior wall and cause urge symptoms or de novo anterior compartment prolapse. Similarly, sacrospinous ligament fixation (SSLF) increases the risk of anterior vaginal wall prolapse, as it deviates the vaginal axis towards the posterior. However, laparoscopic lateral mesh suspension has recently become popular because it preserves the normal position of the vaginal axis, preventing such complications. A previous study found that the pectineal ligament (Cooper's ligament) is composed of stronger and more durable tissue than the sacrospinous ligament and arcus tendineus of the fascia pelvis. This structure is robust and can hold sutures well, and it is possible to find sufficient material for a suture in the lateral part of the iliopectineal ligament, facilitating pelvic floor reconstruction. This segment of the ligament is located at the second sacral vertebra (S2) level, which is the optimal level for the physiological axis of the vagina. S2 level serves as the anchor point for the physiological axis of the vagina. Further studies have demonstrated that laparoscopic pectopexy provides outcomes comparable to those of laparoscopic sacrocolpopexy for supporting the apical compartment during intermediate follow-up duration. The current study aimed to investigate the level of anatomical correction following laparoscopic pectopexy and compare the vaginal axis of patients with apical genital prolapse to that of nulliparous women using magnetic resonance imaging (MRI).

Read the detailed description

Pelvic organ prolapse (POP) is a significant health concern that has a negative impact on the physical and psychological well-being of women. In fact, the lifetime risk of undergoing POP surgery is 12.6%. The most common form of POP involves defects in the anterior vaginal wall accompanied by apical prolapse. The primary goal of surgical treatment for POP is to alleviate symptoms and restore the anatomy of the pelvic support. The normal position of the vaginal axis is directed posteriorly towards the S3 and S4 vertebrae, lying relatively horizontally to the levator plate, and forming an angle of about 130º between the middle and lower vagina. Sacrocolpopexy (SCP) is considered the gold standard for treating POP, but it alters the normal anatomical position of the vaginal axis towards the sacral promontory, which may increase the abdominal pressure load on the anterior wall and cause urge symptoms or de novo anterior compartment prolapse. Although sacrospinous ligament fixation (SSLF) has promising long-term outcomes for correcting the apical anatomy, it increases the risk of anterior vaginal wall prolapse, like SCP, due to the deviation of the vaginal axis towards the posterior. Recently, laparoscopic lateral mesh suspension, which keeps the vaginal axis close to normal, has become popular. In a previous study, it was found that the pectineal ligament (Cooper's ligament) is composed of stronger and more durable tissue than the sacrospinous ligament and arcus tendineus of the fascia pelvis. This structure is robust and can hold sutures well. Sufficient material for a suture can also be found in the lateral part of the iliopectineal ligament, making pelvic floor reconstruction easier. This segment of the ligament is located at the second sacral vertebra (S2) level, which is the optimal level for the physiological axis of the vagina. S2 level is the anchor point for the physiological axis of the vagina. Further studies have demonstrated comparable outcomes for supporting the apical compartment at intermediate follow-up duration compared to laparoscopic sacrocolpopexy. This study aimed to investigate the level of anatomical correction following Laparoscopic pectopexy and compare the vaginal axis of patients with apical genital prolapse to that of nulliparous women using magnetic resonance imaging (MRI).

03

Conditions studied

  • Pelvic Organ Prolapse

Browse trials for

Keywords

  • Magnetic resonance imaging (MRI)
  • vaginal angle
  • vaginal axis
  • pelvic organ prolapse (POP)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

In Intervention Group

Inclusion Criteria:

  • Women diagnosed with apical pelvic organ prolapse (POP), who did not require an additional posterior colporrhaphy procedure, and desired to undergo uterus-preserving surgery were scheduled for laparoscopic pectopexy.

Exclusion Criteria:

  • Women with uterine size greater than 10 cm or a pelvic mass that may alter or interfere with accurate measurement.
  • Women with any congenital or acquired anatomical or reproductive anomaly.
  • Women diagnosed with enterocele through transperineal ultrasound prior to enrollment.
  • Women who require hysterectomy or concomitant pelvic organ prolapse (POP) or anti- incontinence procedure.
  • Women with abnormal uterine bleeding.
  • Women with abnormal cervical screening test results.

In Control Group

Inclusion Criteria:

  • Nulliparous women without pelvic organ prolapse (asymptomatic grade 1 or less) who presented to the outpatient clinic with complaints other than POP symptoms (e.g., menstrual irregularity) were randomly selected and assigned as the control group.

Exclusion Criteria:

  • Women who have given birth previously.
  • Women with a history of pelvic organ prolapse or any pelvic floor disorders.
  • Women who have undergone pelvic surgery.
  • Women with any congenital or acquired anatomical or reproductive anomaly.
  • Women with abnormal uterine bleeding.
  • Women with abnormal cervical screening test results.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Active comparator
    procedure: laparoscopic pectopexy

    MRI evaluation will be conducted on eleven participants who underwent laparoscopic pectopexy surgery after one month.

    Procedure: laparoscopic pectopexy

  • No intervention
    Nulliparous women with no uterovaginal prolapsed

    Ten nulliparous participants with no uterovaginal prolapsed will be evaluate by MRI

Interventions

  • Procedurelaparoscopic pectopexy

    Women with pelvic organ prolapse and suitable indications underwent laparoscopic pectopexy.

06

What researchers measure

Primary outcomes

  1. Anatomic Success

    anatomic success will be evaluated by using magnetic resonance imaging. Vaginal axis (distance to spin ischiadic a and sacrum) will be measure on three plane

    Time frame: 3 months

Secondary outcomes

  1. Urge Symptoms stres incontinence

    UDI-6 Th e UDI-6 was developed to evaluate the functions of the bladder and to establish which symptom causes the problem. It comprises 6 questions. Th e fi rst 2 questions are related to irritative symptoms (urgency, frequency, and pain), questions 3 and 4 are related to stress incontinence, and the last 2 questions are related to obstructive or voiding diffi culty symptoms. High UDI-6 scores show the severity of the urogenital complaints

    Time frame: 3 month

  2. Sexual functions

    The FSFI evaluates sexual functioning in women and comprises of 19 questions with different answer choice scales referring the sexual life in the previous 4 weeks. The answer choices in the FSFI carry a number of points and are summed to obtain six domain scores and an overall score. For the latter, there is a threshold at 26.55 which means tFhat all values below are classed as indicating female sexual dysfunction (FSD). The domain scores are obtained as the sum of points attributed to questions in that domain multiplied by the domain factor.

    Time frame: 3 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wang H, Shen J, Li S, Gao Z, Ke K, Gu P. The feasibility of uterine-vaginal axis MRI-based as evaluation of surgical efficacy in women with pelvic organ prolapse. Ann Transl Med. 2022 Apr;10(8):447. doi: 10.21037/atm-22-1173. PubMed 35571410 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jun 2023, 5 months after the start.

Of 162 non-industry interventional studies with no phase under Pelvic Organ Prolapse, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 5 months is below that.

Counting every sponsor, half of 179 studies reached it within 23 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2023
First posted
May 26, 2023
StartActual
Jan 4, 2023
Primary completionEst.
Jun 4, 2023
CompletionEst.
Jul 1, 2023
Last update
May 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05876975
Lead sponsor
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Responsible party
fatih sahin (MD / Principal Investigator, Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization) — Principal investigator
First posted
May 26, 2023
Start date
Jan 4, 2023
Primary completion
Jun 4, 2023 (estimated)
Completion
Jul 1, 2023 (estimated)
Last update
May 26, 2023

Study contacts

Fatih Şahin, MD
Contact
fatih_sahin67@hotmail.com
+905447430167
Murat i Toplu, MD
Contact
mitoplu@gmail.com
+905317262517
fatih şahin, MD
principal investigator · Prof. Dr. Cemil Tascıoglu City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion